Future research should explore therapeutic strategies targeting specific signaling pathways, such as Rac1, to mitigate the pro-metastatic effects of obesity-driven insulin resistance. This evidence concerns the gene RAC1 and obesity due to melanocortin 4 receptor deficiency.